Welcome to our dedicated page for Ligand Pharma SEC filings (Ticker: LGNDZ), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Ligand Pharma's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Ligand Pharma's regulatory disclosures and financial reporting.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported a pre-planned option exercise and share sale. On May 1, 2026, he exercised employee stock options for 5,000 shares of common stock at $52.27 per share and sold 5,000 shares of common stock in open-market transactions at weighted-average prices ranging from about $227 to $234 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, indicating they were scheduled in advance rather than timed discretionarily.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon reported a pre-planned option exercise and share sale. On May 1, 2026, he exercised employee stock options for 5,000 shares of common stock at $52.27 per share and sold 5,000 shares of common stock in open-market transactions at weighted-average prices ranging from about $227 to $234 per share. The filing notes these trades were made under a Rule 10b5-1 trading plan adopted on November 24, 2025, indicating they were scheduled in advance rather than timed discretionarily.
LGND Rule 144 notice reporting proposed sales of Common shares. The filing lists 467 shares referenced repeatedly, an issuer listing at Nasdaq, and three recent sale entries by John Kozarich dated 02/02/2026, 03/02/2026, and 04/01/2026 with numeric values shown beside each entry.
LGND Rule 144 notice reporting proposed sales of Common shares. The filing lists 467 shares referenced repeatedly, an issuer listing at Nasdaq, and three recent sale entries by John Kozarich dated 02/02/2026, 03/02/2026, and 04/01/2026 with numeric values shown beside each entry.
Ligand Pharmaceuticals Inc ownership filing: Vanguard Capital Management reported beneficial ownership of 997,637 shares of Common Stock, representing 5% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 997,637 shares and sole voting power for 149,548 shares.
Ligand Pharmaceuticals Inc ownership filing: Vanguard Capital Management reported beneficial ownership of 997,637 shares of Common Stock, representing 5% of the class as of 03/31/2026. The filing states Vanguard has sole dispositive power over 997,637 shares and sole voting power for 149,548 shares.
Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation in an all-cash deal valuing XOMA Royalty at approximately $739 million, paying $39.00 per share plus one contingent value right (CVR) per share tied to 75% of certain Janssen litigation net proceeds.
The transaction will add seven commercial products and more than 100 development-stage royalty assets, expanding Ligand’s portfolio to over 200 assets and strengthening its position as a biopharma royalty aggregator. XOMA’s preferred stock is expected to be converted or redeemed, and XOMA stockholders will receive the CVRs in addition to cash.
Ligand raised its 2026 guidance, now targeting total revenue of $270–$310 million and adjusted EPS of $8.50–$9.50, with royalties of $225–$250 million, and expects the deal to add about $1.50 per share to adjusted EPS in 2027. Closing is expected in the third quarter of 2026, subject to XOMA stockholder and regulatory approvals and other customary conditions.
Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation in an all-cash deal valuing XOMA Royalty at approximately $739 million, paying $39.00 per share plus one contingent value right (CVR) per share tied to 75% of certain Janssen litigation net proceeds.
The transaction will add seven commercial products and more than 100 development-stage royalty assets, expanding Ligand’s portfolio to over 200 assets and strengthening its position as a biopharma royalty aggregator. XOMA’s preferred stock is expected to be converted or redeemed, and XOMA stockholders will receive the CVRs in addition to cash.
Ligand raised its 2026 guidance, now targeting total revenue of $270–$310 million and adjusted EPS of $8.50–$9.50, with royalties of $225–$250 million, and expects the deal to add about $1.50 per share to adjusted EPS in 2027. Closing is expected in the third quarter of 2026, subject to XOMA stockholder and regulatory approvals and other customary conditions.
Ligand Pharmaceuticals Incorporated is asking stockholders to vote at a virtual annual meeting on June 5, 2026. Stockholders will elect eight directors, ratify Ernst & Young LLP as auditor for 2026, approve an advisory say‑on‑pay vote, and consider an amendment and restatement of the 2002 Stock Incentive Plan.
The proxy highlights a royalty‑focused biopharmaceutical model that generated strong 2025 results, including 48% royalty revenue growth and a 42% increase in full‑year adjusted EPS over the prior year. Management attributes this to a lean cost structure, diversified royalty portfolio, and successful partner product launches.
The amended equity plan would add 600,000 shares to the share reserve, eliminate the fungible pool formula, raise the limit on incentive stock options, update director compensation caps, and extend the plan term by ten years. Ligand also emphasizes sustainability initiatives, including a $2.6 million solar investment, and outlines governance practices such as independent committees, a clawback policy, stock ownership guidelines and annual say‑on‑pay votes.
Ligand Pharmaceuticals Incorporated is asking stockholders to vote at a virtual annual meeting on June 5, 2026. Stockholders will elect eight directors, ratify Ernst & Young LLP as auditor for 2026, approve an advisory say‑on‑pay vote, and consider an amendment and restatement of the 2002 Stock Incentive Plan.
The proxy highlights a royalty‑focused biopharmaceutical model that generated strong 2025 results, including 48% royalty revenue growth and a 42% increase in full‑year adjusted EPS over the prior year. Management attributes this to a lean cost structure, diversified royalty portfolio, and successful partner product launches.
The amended equity plan would add 600,000 shares to the share reserve, eliminate the fungible pool formula, raise the limit on incentive stock options, update director compensation caps, and extend the plan term by ten years. Ligand also emphasizes sustainability initiatives, including a $2.6 million solar investment, and outlines governance practices such as independent committees, a clawback policy, stock ownership guidelines and annual say‑on‑pay votes.
Ligand Pharmaceuticals director John W. Kozarich reported selling a total of 467 shares of common stock on April 1, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $199.97 to $204.26 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the sales, Kozarich directly holds 42,253 shares of Ligand Pharmaceuticals common stock.
Ligand Pharmaceuticals director John W. Kozarich reported selling a total of 467 shares of common stock on April 1, 2026 in a series of open-market transactions. The reported weighted-average sale prices ranged from about $199.97 to $204.26 per share.
These transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2025. After the sales, Kozarich directly holds 42,253 shares of Ligand Pharmaceuticals common stock.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon exercised stock options and sold the resulting shares. He exercised 5,000 Employee Stock Options at an exercise price of $52.27 per share, receiving 5,000 shares of common stock.
On the same date, he sold all 5,000 shares in multiple open-market transactions at weighted-average prices ranging from about $198.40 to $204.82 per share, under a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, he directly holds 41,382 shares of Ligand common stock.
Ligand Pharmaceuticals’ CLO & Secretary Andrew Reardon exercised stock options and sold the resulting shares. He exercised 5,000 Employee Stock Options at an exercise price of $52.27 per share, receiving 5,000 shares of common stock.
On the same date, he sold all 5,000 shares in multiple open-market transactions at weighted-average prices ranging from about $198.40 to $204.82 per share, under a written Rule 10b5-1 trading plan adopted on November 24, 2025. Following these transactions, he directly holds 41,382 shares of Ligand common stock.
LGND Rule 144 notice discloses reported dispositions of Common stock. The filing lists an issuer broker entry at UBS Financial Services and shows multiple reported sales by John Kozarich of 467 shares on 01/02/2026, 02/02/2026, and 03/02/2026 with reported amounts $88,532.51, $91,490.02, and $93,632.38 respectively.
LGND Rule 144 notice discloses reported dispositions of Common stock. The filing lists an issuer broker entry at UBS Financial Services and shows multiple reported sales by John Kozarich of 467 shares on 01/02/2026, 02/02/2026, and 03/02/2026 with reported amounts $88,532.51, $91,490.02, and $93,632.38 respectively.